WebDec 12, 2024 · Under the agreement, CSL will have the exclusive license to Arcturus' next generation mRNA technology in the fields of influenza, COVID-19 and other respiratory … WebNov 1, 2024 · CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus …
CSL Announces Closing of Global Collaboration and Licensing …
WebApr 13, 2024 · A new Covid strain behind a surge of infections in India has sparked fears it could also lead to a rise in cases in the UK. Research indicates Arcturus could be one … Web1 hour ago · A new variant of Covid is spreading in India and causing concern. The variant, also known as Omicron subvariant XBB.1.16, was first identified in January and has … cannot resolve symbol myviewholder
CSL Enters Licensing Agreement with Arcturus Therapeutics for …
WebMar 30, 2024 · Arcturus will provide CSL Seqirus with a license to its STARR self-amplifying mRNA technology, LUNAR lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing expertise. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to … WebNov 2, 2024 · CSL Seqirus will lead the development and commercialization of vaccines under the collaboration. Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in ... WebNov 2, 2024 · CSL will pay Arcturus $200 million upfront in the deal. Arcturus will be eligible for more than $1.3 billion in development milestone payments and more than $3 billion in commercial milestones. Arcturus is also eligible for a 40% net profit share for COVID-19 vaccine products and up to double-digit royalties for the other potential products. cannot resolve symbol net